OncoOne Establishes Scientific Advisory Board to Support its Modular PreTarg-it® Platform for Radionuclide Therapies
VIENNA, August 18, 2026--OncoOne, a biotechnology company utilizing its expert knowledge in antibody engineering to support the further growth of targeted radiopharmaceutical therapies globally, announced their new Scientific Advisory Board (SAB) members whose collective expertise spans foundational research, translational medicine and scientific collaborations. The interdisciplinary guidance from the SAB will be instrumental in advancing and broadening the company's PreTarg-it®, a modular platform for pretargeted radioimmunotherapy that separates tumor targeting from radionuclide delivery by using a sequential approach to enable more precise irradiation while limiting damage to surrounding healthy tissue.
"The growing body of promising preclinical data for our PreTarg-it®-based pretargeted radioimmunotherapy programs illustrates its broad potential across oncology indications such as breast, ovarian, colon and lung cancers," commented Randolf Kerschbaumer, Ph.D., CEO of OncoOne. "Our goal is to effectively expand therapeutic windows, improve target accuracy and increase patient safety to enable radioimmunotherapies to better address notoriously underserved cancers. We are looking forward to working closely with this distinguished team of experts whose insights and guidance will be invaluable for the development of our radiopharmaceutical therapies and our collaborations with pharmaceutical and biotechnology partners."
The members of OncoOne's Scientific Advisory Board include:
Danielle Meyrick, PhD, MD
Dr. Danielle Meyrick is a clinician, radiopharmaceutical chemist, and biotech executive with over 20 years of experience in radiopharmaceutical development, clinical strategy, and translational medicine. She has held Chief Medical Officer roles at ITM Radiopharma, Telix Pharmaceuticals, and AdvanCell, leading global clinical development, regulatory strategy, and medical affairs from first-in-human studies through commercialization. With expertise spanning radiochemistry, theranostics, CMC, clinical development, and global regulatory interactions, Dr. Meyrick has also become a trusted advisor to radiopharmaceutical start-ups, investors, and venture capital firms, supporting due diligence, fundraising, strategic partnerships, and company growth across the radiopharma sector.
Hakim Bouterfa, Dr. rer. physiol.
Dr. Hakim Bouterfa is a life sciences entrepreneur, scientist, and biotechnology executive with more than 25 years of international experience in oncology, radiopharmaceuticals, clinical development, and medical affairs. Throughout his career, he has founded, built, and successfully exited several life science companies while leading the development of innovative oncology and radiopharmaceutical programs from early research through commercialization. Dr. Bouterfa has held senior leadership positions including Chief Medical Officer and Board Member at Eckert & Ziegler AG, Co-Founder and CEO of Pentixapharm AG, Founder and Managing Director of Octreopharm GmbH, Vice President at Molecular Insight Pharmaceuticals, and Global Medical Director for Oncology at Novartis. He is currently Founder and Managing Director of Hakim Bouterfa Consulting GmbH, where he advises companies on corporate strategy, clinical development, translational medicine, and value creation in the life sciences sector. Combining a strong scientific foundation in molecular biology and translational medicine with extensive executive leadership experience, Dr. Bouterfa is recognized for driving innovation, company growth, and strategic development within the global radiopharmaceutical and oncology landscape.